SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 124 filers reported holding SAGE THERAPEUTICS INC in Q2 2015. The put-call ratio across all filers is 2.96 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2016 | $6,662,000 | +11.0% | 130,472 | +0.1% | 0.01% | +14.3% |
| Q3 2016 | $6,002,000 | +80.9% | 130,334 | +18.4% | 0.01% | +75.0% |
| Q2 2016 | $3,317,000 | +67.5% | 110,084 | +78.3% | 0.00% | +33.3% |
| Q1 2016 | $1,980,000 | -36.7% | 61,752 | +15.2% | 0.00% | -25.0% |
| Q4 2015 | $3,126,000 | +37.6% | 53,624 | -0.1% | 0.00% | +33.3% |
| Q3 2015 | $2,271,000 | -46.0% | 53,671 | -6.9% | 0.00% | -40.0% |
| Q2 2015 | $4,207,000 | +338.2% | 57,631 | +201.6% | 0.01% | +400.0% |
| Q1 2015 | $960,000 | +40.6% | 19,110 | +2.4% | 0.00% | 0.0% |
| Q4 2014 | $683,000 | +24.2% | 18,663 | +6.9% | 0.00% | 0.0% |
| Q3 2014 | $550,000 | – | 17,460 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DAFNA Capital Management LLC | 99,306 | $14,027,000 | 5.76% |
| Casdin Capital, LLC | 312,000 | $44,070,000 | 5.36% |
| Palo Alto Investors LP | 840,372 | $118,703,000 | 4.80% |
| BB BIOTECH AG | 1,071,373 | $151,331,000 | 4.00% |
| TRV GP II, LLC | 37,362 | $5,277,000 | 3.10% |
| Eversept Partners, LP | 43,621 | $6,161,466 | 2.70% |
| RA Capital Management | 350,933 | $49,569,000 | 2.65% |
| Eventide Asset Management | 494,000 | $69,778,000 | 2.56% |
| OAK RIDGE INVESTMENTS LLC | 241,099 | $34,055,000 | 1.88% |
| SUFFOLK CAPITAL MANAGEMENT LLC | 93,000 | $13,136,000 | 1.87% |